MedTrace Logo

ATG Based Conditioning Regimen in HLA Related HSCT for Aggressive T-cell Tumors

NCT02938741 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 130

Last updated 2016-10-25

No results posted yet for this study

Summary

ATG based conditioning regimen in HLA related allogeneic hematopoietic stem cell transplantation for aggressive T-cell tumors: multi-center, open, randomized controlled clinical study

Conditions

  • Lymphoblastic Lymphoma

Interventions

DRUG

Anti-human Thymoglobulin

r-ATG 2.5MG/KG\*4days were used in the conditioning

DRUG

Placebo

r-ATG 2.5MG/KG\*4days were not used in the conditioning

Sponsors & Collaborators

  • Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

    lead OTHER

Principal Investigators

  • xipeng wang, doctor · Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-10-31
Primary Completion
2021-12-31
Completion
2022-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02938741 on ClinicalTrials.gov